Immunoproliferative Disorders  >>  oxaliplatin  >>  Phase 2
Welcome,         Profile    Billing    Logout  

13 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
oxaliplatin / Generic mfg.
NCT00006473: Oxaliplatin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Completed
2
72
US
oxaliplatin, 1-OHP, Dacotin, Dacplat, Eloxatin, L-OHP
National Cancer Institute (NCI)
Angioimmunoblastic T-cell Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Waldenström Macroglobulinemia
02/06
 
NCT00336583: Etoposide, Methylprednisolone, High-dose Cytarabine and Oxaliplatin as 2nd Line Therapy for Non-Hodgkin's Lymphoma (NHL)

Completed
2
27
RoW
Oxaliplatin, etoposide, 40 mg per square meter on days 1 to 4,, methylprednisolone, 500 mg on days 1 to 5,, cytarabine, 2 g per square meter on day 5
Asan Medical Center, Boryung Pharmaceutical Co., Ltd
Non-Hodgkin's Lymphoma
12/06
01/08
NCT01538641: Phase II Evaluation of Gemcitabine- Rituximab-Oxaliplatin Combination (GROC) in Relapsed Aggressive Lymphomas

Completed
2
43
US
Rituximab, Gemcitabine, Oxaliplatin
Auxilio Mutuo Cancer Center
Refractory Aggressive Non-Hodgkin's Lymphoma, Relapsing Aggressive Non-Hodgkin's Lymphoma
08/07
12/08
NCT00169195 / 2005-002344-26: Rituximab, Gemcitabine and Oxaliplatin (R-GEMOX) for Refractory/Relapsed B-cell Lymphoma

Completed
2
49
Europe
Gemcitabine-Oxaliplatin plus Rituximab (R-GEMOX)
Lymphoma Study Association, Hoffmann-La Roche, Sanofi-Synthelabo, Eli Lilly and Company
Diffuse Large Cell Lymphoma
11/12
11/12
NCT01068392: Oxaliplatin and Prednisolone (Ox-P) for Patients With Relapsed or Refractory Marginal Zone B-cell Lymphoma(MZL)

Completed
2
42
RoW
Oxaliplatin, Prednisolone
Dong-A University Hospital, Samsung Medical Center, Asan Medical Center, Chung-Ang University, Kyungpook National University Hospital, Chonnam National University Hospital, Korea Cancer Center Hospital, Korea University
B-cell Lymphomas
09/13
09/14
NCT02808091: Bortezomib With Combination of Gemcitabine, Ifosfamide and Oxaliplatin in Untreated NK/T Cell Lymphoma

Terminated
2
7
RoW
GIFOX-Bortezomib, IMRT, Intensity-modulated radiation therapy
National Cancer Centre, Singapore
Extranodal NK-T-CELL LYMPHOMA
11/13
03/14
RGemOx, NCT01562977 / 2008-007305-36: Study to Evaluate Efficacy and Tolerance of R-GemOx in DLBCL and MCL

Completed
2
82
Europe
Rituximab, Gemcitabine, Oxaliplatin, Dexametasone
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Aggressive Lymphoma, Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma
04/15
04/15
NCT01626664: KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)

Completed
2
71
Europe, US, RoW
KW-0761, mogamulizumab, POTELIGEO®, Pralatrexate, Folotyn, gemcitabine plus oxaliplatin, Gemzar, Eloxatin, GemOx, DHAP, Decadron, Dexasone, Baycadron, Platinol, Depocyt, Ara-C
Kyowa Kirin, Inc.
Adult T-cell Leukemia-Lymphoma
08/15
02/18
NCT02533323: P-Gemox Regimen as First-line Chemotherapy in NK/T Lymphoma Patiens

Terminated
2
50
RoW
gemcitabine, Gemzar, oxaliplatin, Eloxatin, pegaspargase, Oncaspar
Sun Yat-sen University
Lymphoma, Extranodal NK-T-Cell
09/16
01/17
NCT00452374: Oxaliplatin, Fludarabine, Cytarabine and Rituximab in Richter's Syndrome, Refractory CLL and PLL

Completed
1/2
48
US
Cytarabine, Ara-C, Cytosar, DepoCyt, Cytosine arabinosine hydrochloride, Fludarabine, Fludara, Fludarabine Phosphate, Oxaliplatin, Eloxatin, Rituximab, Rituxan
M.D. Anderson Cancer Center, Sanofi
Leukemia
01/11
01/11
NCT00954005: Study With Rituximab-Gemcitabine/Oxaliplatin in Relapsed Indolent Lymphoma

Terminated
1/2
56
Europe
Therapy with Rituximab, Gemcitabine and Oxaliplatin, Rituximab = Mabthera, Rituxan, Gemcitabine = Gemzar, Oxaliplatin = Eloxatin
German Low Grade Lymphoma Study Group
Indolent Lymphoma
06/11
06/12
NCT00472849: Oxaliplatin, Fludarabine, Cytarabine, and Rituximab in Patients With Richter's Transformation and Leukemias

Checkmark aggressive relapsed/refractory chronic lymphocytic leukemia or Richter syndrome
Jul 2013 - Jul 2013: aggressive relapsed/refractory chronic lymphocytic leukemia or Richter syndrome
Checkmark P1/2 data release
Jun 2011 - Jun 2011: P1/2 data release
Completed
1/2
92
US
Oxaliplatin, Fludarabine, Fludara, Cytarabine, Cytosar, Ara-C, Rituximab, Rituxan, Pegfilgrastim, Neulasta
M.D. Anderson Cancer Center, Sanofi
Richter's Transformation, Leukemia
02/12
02/12
NCT01562990 / 2011-003849-18: Phase Ib/II Study of the Efficacy and Safety of the R-CMC544/R-GEMOX Combination in Diffuse Lage B-cell Lymphoma at First or Second Relapse

Completed
1/2
11
Europe
Rituximab, CMC544, Gemcitabine and Oxaliplatine
The Lymphoma Academic Research Organisation, Pfizer
Diffuse Large B-Cell Lymphoma
08/14
03/16

Download Options